Volume | 10,252 |
|
|||||
News | (1) |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
NRX Pharmaceuticals Inc | NRXPW | NASDAQ | Equity Warrant |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
0.38 | 0.252 | 0.39 | 0.40 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume |
---|---|---|---|---|
48 | 10,252 | 0.3110116 | 3,188 | - |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
10:29:18 | 5 | 0.385 | USD |
NRX Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
34.64M | 86.61M | - | 0 | -30.16M | -0.35 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
News NRX Pharmaceuticals
Date | Time | Source | Heading |
---|---|---|---|
1/10/2025 | 07:32 | Edgar (US Regulatory) | Form 8-K - Current report |
11/20/2024 | 08:00 | Edgar (US Regulatory) | Form 8-K - Current report |
11/15/2024 | 16:24 | Edgar (US Regulatory) | Form 8-K - Current report |
11/14/2024 | 15:01 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
11/14/2024 | 11:21 | Edgar (US Regulatory) | Form S-1 - General form for registration of securities under.. |
10/31/2024 | 07:00 | Edgar (US Regulatory) | Form 8-K - Current report |
10/15/2024 | 15:52 | Edgar (US Regulatory) | Form 8-K - Current report |
10/11/2024 | 15:53 | Edgar (US Regulatory) | Form 8-K - Current report |
9/05/2024 | 15:18 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
5/23/2024 | 15:00 | Edgar (US Regulatory) | Form 8-K - Current report |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
NRXPW Historical
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Year | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
5 Years | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour. |